Benchmark Genetics’ CEO, Geir Olav Melingen, has decided to resign from his position. He will remain in the company for a transition period to support a smooth handover to the next CEO.
Geir Olav has been with the Benchmark Group for six years, playing a key role in the growth of its aquaculture genetics business. He served as head of the genetics business area in Benchmark Holdings before being appointed CEO of Benchmark Genetics on April 1, 2025, following the company’s transition to independent ownership under Novo Holdings.
Novo Holdings has initiated the search process for a new CEO. In the interim, Aleks Engel, partner at Novo Holdings, will assume the role of interim CEO, supported by a dedicated team from Novo Holdings.
“It has been a privilege to lead Benchmark Genetics through an exciting phase of growth and transition. I believe strongly in the company's future and the potential of its partnership with Novo Holdings,” said Geir Olav Melingen. “This decision reflects a personal career step, and I remain fully committed to ensuring a seamless transition in the period ahead.”
Under Melingen’s leadership, Benchmark Genetics has reinforced its position as a global leader in aquaculture genetics, providing high-quality genetic solutions to salmon, shrimp, and genetic programs worldwide.
“Geir Olav has played a central role in building Benchmark Genetics into a strong and focused organisation with a clear strategic direction,” said Aleks Engel, interim CEO. “On behalf of Novo Holdings and the Board, I want to thank him for his leadership and dedication, and we look forward to working closely with the team during this transition.”
Benchmark Genetics continues its mission to deliver world-leading genetic solutions that support sustainable growth in global aquaculture. Novo Holdings will be supporting the company’s next strategic phase in advancing aquaculture genetics globally.
